Hyperuricemia complicated with hypertension
Conditions
Interventions
The Topiroxostat treatment group is administrated 40mg/day of Topiroxostat at the beginning of treatment period and then titrated up to 160mg/day to maintain serum uric acid levels less than 6 mg/dl.
Sponsors
Jichi Medical University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who meet all of the following criteria are included in this study. 1. Age =>30 and <80 at the time of giving their consent 2. Patients with g out or Hyperuricemia who are untreated or treated with Allopurinol (Serum uric acid > 7.0mg/dL) 3. Hypertensive patients receiving stable antihypertensive treatment at least 3 months at study enrollment 4. 8=<CAVI=<12 at enrollment 5. Written informed consent by his/her own will
Exclusion criteria
Exclusion criteria: Patients who meet any of the following criteria are not eligible for the study 1.History of hypersensitivity to Topiroxostat, Febuxostat or Allopurinol 2.Treated with the following hyperuricemic drugs within 4 weeks before the enrollment: Topiroxostat, Febuxostat, Benzbromarone, Probenecid, Bucolome 3.Under treatment with the following drugs at the enrollment; Probenecid, Bucolome, Benzbromarone, Mercaptopurine or Azathioprine 4.Cancer patients (excluding those completely cured) 5.Patients with gouty arthritis within 2 weeks before enrollment 6.Patients who have high AST or ALT as twice as the upper limit of hospital's reference value 7.Patients with serious liver dysfunction (Child Pugh B, C) 8.Patient with renal dysfunction (eGFR <30ml/min/1.73m2) 9.Patients with severe heart failure (CHF, NYHA functional class 3 and 4) 10.History of acute coronary syndrome or stroke within 3 months 11.Patients who participated in another clinical study or clinical trial in the six months prior to the confirmation of eligibility (excludes observational studies) 12.Patients who are considered to be inappropriate for the participation in this study by the investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in CAVI from baseline to 24 weeks | — |
Countries
Japan
Contacts
Public ContactBEYOND Secretariat
Satt Co., Ltd. Clinical research steering group
Outcome results
None listed